The Cambridge Questionnaire for Apathy and Impulsivity Traits (CamQUAIT): a novel assessment tool for frontotemporal lobar degeneration-related syndromes - Lansdall, CJ; Williams, R; Coyle-Gilchrist, I; Murley, AG; Rouse, MA; Bateman, A; Rowe, JB (medRxiv, 2024)
State of the Art Apathy and impulsivity are common in syndromes associated with frontotemporal lobar degeneration (FTLD). They are associated with high carer distress and poor patient outcomes. There are limited treatment options and progress has been hindered by a lack of appropriate outcome measures. This study aimed to develop a carer-rated questionnaire oriented to people with syndromes associated with FTLD.Methodology Principal component and Rasch analysis were conducted on carer-, clinician- and patient-reported questionnaires and performance-based tests of behavioural change in the “Pick’s Disease and Progressive Supranuclear Palsy Prevalence and Incidence” (PiPPIN) study. We identified two key components which informed subsequent item development for a novel scale which we call the Cambridge Questionnaire for Apathy and Impulsivity Traits (CamQUAIT). The resulting scale comprised two subscales assessing “motivation and support” (CamQUAIT-M) and “impulsivity and challenging behaviours” (CamQUAIT-C). An independent sample of 132 carers for people with FTLD-associated syndromes completed the CamQUAIT, along with a battery of existing measures. The CamQUAIT was reduced to 15 items following Rasch analysis.Results Both subscales showed good construct validity as assessed by high Person separation index (CamQUAIT-M=0.9; CamQUAIT-C=0.7) and Cronbach’s alpha (CamQUAIT-M=0.9; CamQUAIT-C=0.8). The subscales correlated moderately with each other (r=0.376, p<0.001), and with existing measures of behavioural change.Conclusion The CamQUAIT is a targeted measurement tool to assess apathy, impulsivity, and related behavioural change in the context of FTLD-related syndromes. The scale demonstrates good measurement properties and is sensitive to group differences, providing a suitable outcome measure to evaluate novel symptomatic treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been funded by the Medical Research Council (MC_UU_00030/14; MR/T033371/1), the Wellcome Trust (220258), the NIHR Cambridge Biomedical Research Centre (NIHR203312), the Cambridge Centre for Parkinson-plus and the Holt fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Cambridge Research Ethics Committee (ref. 12/EE/0475)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesFor enquiries related to source data, please contact the corresponding author. A material transfer agreement may be required, to comply with the terms of consent and GDPR.